---
title: "Cormedix 完成了對 Melinta Therapeutics 的收購，提高了財務指引，並宣佈了新的領導團隊"
description: "- CorMedix 的一項變革性交易，擴展和多樣化了公司的商業產品組合，包含七種創新藥物產品以及一個具有近期收入增長潛力的管線擴展指示 -"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/255617485.md"
published_at: "2025-09-02T12:09:09.000Z"
---

# Cormedix 完成了對 Melinta Therapeutics 的收購，提高了財務指引，並宣佈了新的領導團隊

> - CorMedix 的一項變革性交易，擴展和多樣化了公司的商業產品組合，包含七種創新藥物產品以及一個具有近期收入增長潛力的管線擴展指示 -

\- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -

### Related Stocks

- [CRMD.US - CorMedix](https://longbridge.com/zh-HK/quote/CRMD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CorMedix Investor Day: Melinta Deal Fuels Shift to Multi-Product Pharma, Rezzayo Q2 Data Ahead | CorMedix (NASDAQ:CRMD) announced a strategic shift from a single-product renal company to a diversified specialty pharma | [Link](https://longbridge.com/zh-HK/news/275523726.md) |
| CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback | CorMedix Inc. (NASDAQ:CRMD) has announced a share repurchase program approved by its board, allowing for up to $75 milli | [Link](https://longbridge.com/zh-HK/news/275654068.md) |
| Analyst Expectations For Cormedix's Future | In the past three months, six analysts have rated Cormedix (NASDAQ:CRMD), showing a mix of bullish to bearish sentiments | [Link](https://longbridge.com/zh-HK/news/275609296.md) |
| CorMedix Announces $75 Mln Share Buyback Program | CorMedix Therapeutics (CRMD) has announced a share repurchase program of up to $75 million, approved by its Board, to be | [Link](https://longbridge.com/zh-HK/news/274523823.md) |
| CorMedix Hosts Analyst Day to Showcase Pipeline and Growth Drivers | CorMedix Inc. will host an analyst day on February 10, 2026, in New York, featuring presentations from key opinion leade | [Link](https://longbridge.com/zh-HK/news/274158609.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。